Additional and a second s	58					
AGENCY USE ONLY (Leave blank)     Prevent of the second of the seco	e to average 1 nour per response, including the time for reviewing instruction, searching existing data source ewing the collection of information. Send comments regarding this burger est) hate nv any other aspect of th den. to washington nearcourters Services, Directoriste for inform: on Operations all Reports, 2018 Jetters ice of Management and Budget, Paperwork Reduction Project (0264<185), Washington, DC 20503.					
A. TILL AND SUBTICLE       A rapid method for detection and identification of flaviviruses by polymerase chain reaction and nucleic acid hybridization       S. FUNCING NUMBERS         F. AUTROR(S)       Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Watts DM, Hayes CC       PE - 62787A PR - 3M16270A870         F. Naval Medical Research Institute       Report NUMBER S01 Wisconsin Avenue       Bethesda, Maryland 20889-5607         SPONSORING/MONTORING AGENCY NAME(S) AND ADDRESS(ES) Naval Medical Research and Development Command Mational Naval Medical Center       NMRI 94-14         Building J, Tower 12       Bethesda, Maryland 20889-5606       Performence         1. SUPPLEMENTARY NOTES       Performence       DN/43578         Pethods, Maryland 20889-5606       The sector of Virology 1994 Vol.134 pp 2:9-37       DN/243578         94-18495       12b. DISTRIBUTION / AVAILABULTY STATEMENT       12b. DISTRIBUTION CODE         Approved for public release; distribution is unlimited.       DTIC QUALITY INSPECTED #         94       14       159         4. SUBLECT TERMS       15. NUMBER OF F 9         diagnostic tests; polymerase chain reaction; flaviviruse; oligomeric DNA       15. NUMBER OF F 9         4. SUBLECT TERMS       16. FRICE CODE         5. SCUENTY CLASSIFICATION       16. SECUENTY CLASSIFICATION       20. LIMITATION OF						
A rapid method for detection and identification of flaviviruses by polymerase chain reaction and nucleic acid hybridization E. AUTHOR(S) Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Watts DM, Hayes CC PERFORMING ORGANIZATION NAME(S) AND ADDRESS(GS) Naval Medical Research Institute Commanding Officer B901 Wisconsin Avenue Bethesda, Maryland 20889-5607 - SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(GS) National Naval Medical Research and Development Command National Naval Medical Center Building 1, Tower 12 8901 Wisconsin Avenue Bethesda, Maryland 2089-5606 - SUPPLEMENTARY NOTES Reprinted from: Archives of Virology 1994 Vol.134 pp. 21-37 - SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(C) - SUPPLEMENTARY NOTES Reprinted from: Archives of Virology 1994 Vol.134 pp. 21-37 - DISTRIBUTION / AVAILABULITY STATEMENT Approved for public release; distribution is unlimited. - ASSTRACT (Maximum 200 words) - SUBALCT TERMS diagnostic tests; polymerase chain reaction; flavivirus; oligomeric DNA - SUBALCT TERMS -						
S. AUTHOR(S) Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Natts DM, Hayes CC Puri B; Henchal EA, Burans J, Porter KR, Notes Puri B; Henchal EA, Burans J, Puri B, Bitter H, Hayes CC Puri B; Henchal EA, Burans J, Puri B, Harden J, Puri B, Bitter H, Burans J, Puri B, Bitter H, Burans J, Burans J, Puri B, Bitter H, Burans J, Puri B, Bitter H, Burans J, Barden J						
Puri B; Henchal EA, Burans J, Porter KR, Nelson W, Watts DH, Hayes CC       WU - 1299         PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)         Naval Medical Research Institute Commanding Officer       8. PERFORMING ORGANIZA REPORT NUMBER         S901 Wisconsin Avenue Bethesda, Maryland 20889-5607       8. PERFORMING ORGANIZA NATIONAL Medical Research and Development Comman National Naval Medical Center         Building J, Tower 12       Building J, Tower 12         Byonsonsin Avenue Bethesda, Maryland 20889-5606       DN243578         Pethesda, Maryland 20889-5606       DN243578         N.SUPPLEMENTARY NOTES       Reprinted from: Archives of Virology 1994 Vol.134 pp. 20-37         22a. DISTRIBUTION / AVAILABILITY STATEMENT       12b. DISTRIBUTION CODE         Approved for public release; distribution is unlimited.       94-18495 Words)         3. ABSTRACT (Maximum 200 words)       DTIC QUALITY INSPECTED X         94       14       15. NUMBER OF F 9         4. SUBJICT TERMS       15. NUMPER OF J         4. SUBJICT TERMS       15. NUMPER OF J         4. SUBJICT TERMS       16. SIGURITY CLASSIFICATION       15. NUMPER OF J         7. SECURITY CLASSIFICATION       16. SIGURITY CLASSIFICATION       17. SIGURITY CLASSIFICATION						
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Naval Medical Research Institute Commanding Officer Both Wisconsin Avenue Bethesd, Maryland 20889-5607       8. PERFORMING ORGANIZA NMRI 94-14         SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(F) Naval Medical Research and Development Comman National Naval Medical Center Building 1, Tower 12 8901 Wisconsin Avenue Bethesd, Maryland 20889-5606       NMRI 94-14         Bethesd, Maryland 20889-5606       Image: Commanding Officer Building 1, Tower 12 8901 Wisconsin Avenue Bethesd, Maryland 20889-5606       Image: Commanding Officer Building 1, Tower 12 8901 Wisconsin Avenue Bethesd, Maryland 20889-5606         Suppression 1: SUPPLEMENTARY NOTES Reprinted from: Archives of Virology 1994 Vol.134 pp 20-37       Image: Commandian Officer Building 1, Tower 12 8001 Wisconsin Avenue Bethesd, Maryland 20889-5606         94-18495 Word       Image: Commandian Officer Bay Stract (Maximum 200 words)       Image: Commandian Officer Bay Stract (Maximum 200 words)         94-18495 Word       Image: Commandian Officer Bay Stract (Maximum 200 words)       Image: Commandian Officer Bay Stract (Maximum 200 words)         94-18495 Word       Image: Commandian Officer Bay Stract (Maximum 200 words)       Image: Commandian Officer Bay Stract (Maximum 200 words)         94-18495 Word       Image: Commandian Officer Bay Stract (Maximum 200 words)       Image: Commandian Officer Bay Stract (Maximum 200 words)         Image: Stract (Maximum 200 words)       Image: Commandian Officer Bay Stract (Commandian O						
Naval Medical Research Institute Commanding Office 8901 Wisconsin Avenue Bethesda, Maryland 20889-5607       NMRI 94-14         SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESSIF Naval Medical Research and Development Command National Naval Medical Center Building 1, Tower 12 8901 Wisconsin Avenue Bethesda, Maryland 20889-5606       SPONSORING/MONITOR SPONSORING/MONITOR Bethesda, Maryland 20889-5606         1. SUPPLEMENTARY NOTES Reprinted from: Archives of Virology 1994 Vol.134 pp. 20-37       DN243578         22. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.       12b. DISTRIBUTION CODE         3. ASSTRACT (Maximum 200 words)       DTTC QUALITY INSPECTED N         94 6 14 159       15. NUMBER OF F 9         4. SUBJECT TERMS diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA probes       15. NUMBER OF I 9         7. SECURITY CLASSIFICATION       18. SECURITY CLASSIFICATION       15. SECURITY CLASSIFICATION         7. SECURITY CLASSIFICATION       18. SECURITY CLASSIFICATION       20. LIMITATION O	TION					
Southanding Other       NMRI 94-14         Bethesda, Maryland 20889-5607       NMRI 94-14         Sponsonkir/Monitoring Actiner Make(s) AND ADDRESSIG       Sponsonkir/Monitoring Actiner Reformant Partial Statement Commany Pational Naval Medical Center         Building 1, Tower 12       Sponsonkir/Monitoring Actiner Reformany Pational Naval Medical Center         Building 1, Tower 12       DN243578         Bethesda, Maryland 20889-5606       DN243578         Sopretentiation Avenue       Bethesda, Maryland 20889-5606         Suppretentiater Notes       DN243578         Reprinted from: Archives of Virology 1994 Vol.134 pp. 27-37         22. DISTRIBUTION/AVAILABULTY STATEMENT         Approved for public release; distribution is unlimited.         3. ABSTRACT (Maximum 200 words)         944 6 1 4 159         4. SUBJECT TERMS         diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA         9       15. NUMBER OF F         9       Steurity CLASSIFICATION         18. SECURITY CLASSIFICATION       18. SECURITY CLASSIFICATION         19. SECURITY CLASSIFICATION       18. SECURITY CLASSIFICATION						
Dethesda, Maryland 20889-5607         Index 9.4 Hit         Index 9.4 Hit         Naval Medical Research and Development Commany National Naval Medical Center Building 1, Tower 12 ByOl Wisconsin Avenue Bethesda, Maryland 20889-5606       Index 9.4 Hit         Index 9.4 Hit         DN243578         Bethesda, Maryland 20889-5606         1. SUPPLEMENTARY NOTES         Reprinted from: Archives of Virology 1994 Vol.134 pp=2:1-37         TRIBUTION / AVAILABILITY STATEMENT         Approved for public release; distribution is unlimited.         DTIC QUALITY INSPECTED #         94 - 18495 00 F         DTIC QUALITY INSPECTED #         SUBJECT TERMS         94 6 1 4 159         IS SUBJECT TERMS         SUBJECT TERMS         of diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA         IS SUBJECT TERMS         of security CLASSIFICATION         SIGURITY CLASSIFICATION         IS SUBJECT TERMS         SIGURITY CLASSIFICATION         SIGURITY CLASSIFICATION						
SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESSION (INC) MONITORING AGENCY REPORT NUMBER National Naval Medical Center Building 1, Tower 12       Sponsorina Avenue       Sponsorina Avenue       DN243578         Building 1, Tower 12       DN243578       DN243578       DN243578         Byol Wisconsin Avenue       DN243578       DN243578         Bethesda, Maryland 20889-5606       DN243578       DN243578         Supplementary Notes       Reprinted from: Archives of Virology 1994 Vol.134 pp 20-37       DN243578         Za. DISTRIBUTION / AVAILABILITY STATEMENT       12b. DISTRIBUTION CODE         Approved for public release; distribution is unlimited.       DTTC QUALITY INSPECTED S         94-18495       DTTC QUALITY INSPECTED S         944 6 14 159       15. NUMBER OF F         1. SUBJECT TERMS       15. NUMBER OF F         grapostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA       15. NUMBER OF F         1. SUBJECT TERMS       15. SECURITY CLASSIFICATION       15. SECURITY CLASSIFICATION         1. SECURITY CLASSIFICATION       16. SECURITY CLASSIFICATION       15. SECURITY CLASSIFICATION						
National Naval Medical Center         Building 1, Tower 12         8901 Wisconsin Avenue         Bethesda, Maryland 20889-5606         1. SUPPLEMENTARY NOTES         Reprinted from: Archives of Virology 1994 Vol.134 pp. 21-37         2a. DistRiBUTION/AVAILABILITY STATEMENT         Approved for public release; distribution is unlimited.         3. ABSTRACT (Maximum 200 words)         DTIC QUALITY INSPECTED #         94 - 18495         94 - 18495         94 - 18495         94 - 18495         94 - 18495         95 - 18495         94 - 18495         94 - 18495         94 - 18495         94 - 18495         95 - 18495         94 - 18495         95 - 18495         94 - 18495         95 - 18495         95 - 18495         96 - 18495         97 - 18495         98 - 18495         99 - 18495         90 - 18495         91 - 185         92 - 18495         93 - 18495         94 - 18495         94 - 18495         95 - 18495         96 - 184 - 159         15. NUMEER OF F         9 <tr< td=""><td>ING ER</td></tr<>	ING ER					
Dulluing 1, 10WE 12       UN243578         BOIL WISCONSIN Avenue       Bethesda, Maryland 20889-5606         1. SUPPLEMENTARY NOTES       Reprinted from: Archives of Virology 1994 Vol.134 pp. 20-37         2a. DISTRIBUTION/AVAILABILITY STATEMENT       12b. DISTRIBUTION CODE         Approved for public release; distribution is unlimited.       12b. DISTRIBUTION CODE         3. ABSTRACT (Maximum 200 words)       DTTC QUALITY INSPECTED A         94 - 18495       000         94 - 18495       000         94 - 18495       000         94 - 18495       000         94 - 18495       000         94 - 18495       000         94 - 18495       000         94 - 18495       000         94 - 18495       000         94 - 18495       000         95       0000         96       14       159         15. NUMBER OF F       15. NUMBER OF F         96       16. PRICE CODE       16. PRICE CODE         15. SECURITY CLASSIFICATION       19. SECURITY CLASSIFICATION       20. LIMITATION OF						
Distribution (Arctine         Dethesda, Maryland 20089-5606         1. SUPPLEMENTARY NOTES         Reprinted from: Archives of Virology 1994 Vol.134 pp. 21-37         Data ClistRiBUTION / AVAILABILITY STATEMENT         Approved for public release; distribution is unlimited.         3. ABSTRACT (Maximum 200 words)         DTIC QUALITY INSPECTED #         94-18495         94-18495         000000000000000000000000000000000000						
1. SUPPLEMENTARY NOTES         Reprinted from: Archives of Virology 1994 Vol.134 pp. 29-37         22. DISTRIBUTION/AVAILABILITY STATEMENT         Approved for public release; distribution is unlimited.         3. ABSTRACT (Maximum 200 words)         94-18495 000         95-18495 000         95-18495 000         95-18495 000         95-18495 000         95-18495 000						
Reprinted from: Archives of Virology 1994 Vol.134 proved-37         2a. DISTRIBUTION/AVAILABILITY STATEMENT         Approved for public release; distribution is unlimited.         3. ABSTRACT (Maximum 200 words)         94-18495 000         95-18400         95-18400         95-18400         95-18400         95-18400         95-18400     <						
Approved for public release; distribution is unlimited. 3. ABSTRACT (Maximum 200 words) 94-18495 (07) DTIC QUALITY INSPECTED # 944-18495 (07) 944-18495 (07) DTIC QUALITY INSPECTED # 944-18495 (07) 944-18495 (07) 944-18495 (07) 15. NUMBER OF F 15. NUMBER OF F 16. PRICE CODE 5. SECURITY CLASSIFICATION [18. SECURITY CLASSIFICATION [19. SECURITY CLASSIFICATION ]20. LIMITATION O						
23. DISTRIBUTION / AVAILABILITY STATEMENT       12b. DISTRIBUTION CODE         Approved for public release; distribution is unlimited.       12b. DISTRIBUTION CODE         3. ABSTRACT (Maximum 200 words)       DTIC QUALITY INSPECTED #         94-18495/07       DTIC QUALITY INSPECTED #         944-18495/07       DTIC QUALITY INSPECTED #         945-18495/07       DTIC QUALITY INSPECTED #         946-18495/07       DTIC QUALITY INSPECTED #         947-18495/07       DTIC QUALITY INSPECTED #         957-1949/07 <td></td>						
Approved for public release; distribution is unlimited. 3. ABSTRACT (Maximum 200 words) 94-18495 00 94-18495 00 DTIC QUALITY INSPECTED & 94-18495 00 94-18495 00 05-1000 00 05-1000 00 15. NUMBER OF F 15. NUMBER OF F 16. PRICE CODE 15. SECURITY CLASSIFICATION 16. SECURITY CLASSIFICATION 20. LIMITATION O						
Approved for public release; distribution is unlimited. 3. ABSTRACT (Maximum 200 words) 94-18495 007 DTIC QUALITY INSPECTED & 94-18495 007 94-18495 007 DTIC QUALITY INSPECTED & 94-18495 007 94-18495 007 94-18495 007 94-18495 007 94-18495 007 94-18495 007 15. NUMBER OF F 9 15. NUMBER OF F 9 16. PRICE CODE 7. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 20. LIMITATION O						
94-18495 DTIC QUALITY INSPECTED N 94-18495 DTIC QUALITY INSPECTED N 95-18400 DTIC QU						
3. ABSTRACT (Maximum 200 words) 94-18495 07 DTIC QUALITY INSPECTED M 94-18495 07 94-18495 07 94-18495 07 94-18495 07 9 9 9 9 15. NUMBER OF F 9 16. PRICE CODE 15. NUMBER OF F 9 16. PRICE CODE 15. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 20. LIMITATION OF						
94-18495 OF 94-18495 OF 9 15. NUMBER OF 9 15. NUMBER OF 9 15. NUMBER OF 9 16. FRICE CODE 15. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 11. SECURITY CLASSIFICATION 15. SECURITY CLASSIFICATION 16. SECURITY CLASSIFICATION 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 10. SECURITY CLASSIFICATION 11. SECURITY SECURITY CLASSIFICATION 11. SECURITY S						
94-18495 OT 94-18495 OT 94-18495 OT 94-18495 OT 94-18495 OT 94-18495 OT 94-18495 OT 94-18495 OT 95-100 IN 95-100 IN 9-15-NUMBER OF 9-15-NUMBER OF						
94-18495 07 94-18495 07 94-18495 07 94-18495 07 94-18495 07 9 9 9 9 9 9 15. NUMBER OF P 9 16. PRICE CODE 15. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 20. LIMITATION OF						
94-18495 OF 94-18495 OF 94-18495 OF 94-18495 OF 95-25-25-25 DTIC QUALITY INSPECTED # 94-18495 OF 95-25-25 95-25-25 DTIC QUALITY INSPECTED # 95-25-25 95-25-25 15. NUMBER OF F 9 15. NUMBER OF F 9 16. PRICE CODE 15. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 10. DEFENT 20. LIMITATION O						
94-18495 MILL QUALITY INSPECTED & 94-18495 95-20 94-18495 95-20 95						
94-18495 000 94-18495 000 94-18495 000 94-18495 000 95-10-10-10-10 05-10-10-10-10-10 05-10-10-10-10-10-10-10-10-10-10-10-10-10-						
94-18495 OF 94-18495 OF 94-18455 OF 94-184555 94-1845555 94-1845555 94-1845555 94-1845555 94-1845555 94-1845555 94-1845555 94-1845555 94-1845555 94-1845555 94-1845555 94-18455555 94-18455555 94-18455555 94-184555555 94-184555555 94-18455555555555555555555555555555555555						
94 6 14 159 Minimum Minimum M	•					
<b>94614</b> <b>15. NUMBER OF P</b> <b>4. SUBJECT TERMS</b> diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA <b>5. SECURITY CLASSIFICATION</b> <b>18. SECURITY CLASSIFICATION</b> <b>19. SECURITY CLASSIFICATION</b> <b>10. LIMITATION O</b> <b>11. SECURITY CLASSIFICATION</b> <b>12. SECURITY CLASSIFICATION</b> <b>13. SECURITY CLASSIFICATION</b> <b>14. SECURITY CLASSIFICATION</b> <b>15. NUMBER OF P</b> <b>16. PRICE CODE</b> <b>16. DRICE CODE</b> <b>17. SECURITY CLASSIFICATION</b> <b>18. SECURITY CLASSIFICATION</b> <b>19. SECURITY CLASSIFICATION</b> <b>19. SECURITY CLASSIFICATION</b> <b>10. LIMITATION O</b> <b>11. NUMBER OF P</b> <b>11. NUMBER OF P</b> <b>13. NUMBER OF P</b> <b>14. PRICE CODE</b> <b>15. NUMBER OF P</b> <b>15. NUMBER OF P</b> <b>15. NUMBER OF P</b> <b>16. PRICE CODE</b> <b>17. SECURITY CLASSIFICATION</b> <b>18. SECURITY CLASSIFICATION</b> <b>19. SECURITY CLASSIFICATION</b> <b>19. SECURITY CLASSIFICATION</b> <b>10. LIMITATION O</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>12. SECURITY CLASSIFICATION</b> <b>13. SECURITY CLASSIFICATION</b> <b>14. SECURITY CLASSIFICATION</b> <b>15. SECURITY CLASSIFICATION</b> <b>16. PRICE CODE</b> <b>17. SECURITY CLASSIFICATION</b> <b>18. SECURITY CLASSIFICATION</b> <b>19. SECURITY CLASSIFICATION</b> <b>10. LIMITATION O</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>12. SECURITY CLASSIFICATION</b> <b>13. SECURITY CLASSIFICATION</b> <b>14. SECURITY CLASSIFICATION</b> <b>15. SECURITY CLASSIFICATION</b> <b>15. SECURITY CLASSIFICATION</b> <b>15. SECURITY CLASSIFICATION</b> <b>15. SECURITY CLASSIFICATION</b> <b>16. PRICE CODE</b> <b>17. SECURITY CLASSIFICATION</b> <b>17. SECURITY CLASSIFICATION</b> <b>18. SECURITY CLASSIFICATION</b> <b>19. SECURITY CLASSIFICATION</b> <b>10. LIMITATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>11. SECURITY CLASSIFICATION</b> <b>12. SECURITY CLASSIFICATION</b> <b>13. SECURT SECURITY CLASSIFICATION</b> <b>14. SECURT SECURT SECURT SECURITY CLASSIFICATION</b> <b>15. SECURT SECU</b>						
94       6       14       159         SUBJECT TERMS         diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA         15. NUMBER OF P         9         15. NUMBER OF P         9         15. NUMBER OF P         9         16. PRICE CODE         0. SECURITY CLASSIFICATION         19. SECURITY CLASSIFICATION         19. SECURITY CLASSIFICATION						
94 6 14 159 A. SUBJECT TERMS diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA probes J. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION O						
94 6 14 159 SUBJECT TERMS diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA probes SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION O						
94 6 14 159 SUBJECT TERMS diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA probes SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION O						
94 6 14 159 A. SUBJECT TERMS diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA probes J. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION O						
U       U						
A. SUBJECT TERMS diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA probes J. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION O						
diagnostic tests; polymerase chain reaction; flaviviruses; oligomeric DNA probes 16. PRICE CODE 15. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 20. LIMITATION O	1615					
16. PRICE CODE 16. PRICE CODE 16. PRICE CODE 16. PRICE CODE 16. PRICE CODE 16. PRICE CODE 16. PRICE CODE	AOC)					
7. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION O	~00					
OF REPORT OF IND PAGE OF RESIDENCE Understand Understand Understand Understand Understand Understand	ABSTR					
Unclassified Unclassified Unclassified Unclassified	ABSTRA					

\*

Arch Virol (1994) 134: 29-37



# A rapid method for detection and identification of flaviviruses by polymerase chain reaction and nucleic acid hybridization

# B. Puri<sup>1,2</sup>, E. A. Henchal<sup>3</sup>, J. Burans<sup>1</sup>, K. R. Porter<sup>1</sup>, W. Nelson<sup>1</sup>, D. M. Watts<sup>1</sup>, and C. G. Hayes<sup>1</sup>

<sup>1</sup> Infectious Disease Threat Assessment Program, Naval Medical Research Institute, Bethesda, <sup>2</sup> Geo-Centers, Inc., Fort Washington, Maryland, <sup>3</sup> Department of Virology, Walter Reed Army Institute of Research, Washington D.C., U.S.A.

Accepted August 18, 1993

Summary. A polymerase chain reaction (PCR) technique was developed and evaluated for the detection of flaviviruses. A set of sense and antisense oligomeric DNA primers were constructed from nucleotide sequences of the conserved region of the genome of several different flaviviruses. Virus specific complementary DNA (cDNA) was prepared by reverse transcription of total RNA extracted from infected cell cultures. Amplified cDNA was identifed by nucleic acid hybridization with specific oligometric internal probes. Various conditions, such as number of cycles and annealing temperature were examined to optimize the detection of viral RNAs from infected cell cultures. Slot blot hybridization with a radioative probe was used to evaluate the sensitivity of PCR amplification. The PCR amplified RNA sequences of dengue 2 (DEN-2), West Nile (WN), St. Louis encephalitis (SLE) and Kunjin (KUN) virus and detected 0.1 to 1 pg of viral RNA. Japanese encephalitis (JE), Yellow Fever virus (YF), DEN-1, 3, and 4 viruses were not amplified. The more frequent occurrence of mismatches in the 3' primer binding site may explain the failure to amplify cDNA of these viruses.

## Introduction

Several of the viruses among the family *Flaviviridae* such as Yellow fever (YF), inced Dengue (DEN), Japanese encephalitis (JE), St. Louis encephalitis (SLE), Kunjin ion (KUN), West Nile (WN) and Tick born encephalitis are important causes of human disease [18]. The laboratory diagnosis of flaviviral infections currently depends upon the demonstration of virus specific antibodies in patient sera on / or the isolation and identification of these viruses followed by serologic typilability Codes



For RA&I

AΒ

#### B. Puri et al.

ing [8, 10, 13]. These methods usually take two or more weeks, thus delaying laboratory diagnosis until long after resolution of the patient's illness. The polymerase chain reaction (PCR) has been shown to be a rapid and sensitive method for diagnosing viral diseases [4, 11, 14]. Recently, Eldadah and others [5] adapted the RT-PCR method for the detection of flaviviruses. In the present study we describe the sensitivity and specificity of a unique set of primers which can be used for amplification of specific regions of the genomes of DEN-2, WN, SLE and KUN viruses.

# Materials and methods

#### Viruses

The cultivation of dengue viruses in C6/36 (Aedes albopictus) cells and titration in LLC-MK<sub>2</sub> (rhesus monkey kidney) cells have been described previously [9]. Dengue virus strains used in this study included DEN-1 (Hawaii), DEN-2 (New Guinea strain). DEN-3 (Thailand, CH53489), and DEN-4 (Dominica, 814669). YF (17D) and KUN viruses were maintained as low passage C6/36 cells culture stocks. JE (Nakayama) and SLE viruses were provided by Dr. E. A. Henchal of Walter Reed Army Institute of Research. The WN virus stock was provided by Dr. R. Shope of Yale University. A rhinovirus stock obtained from ATCC was used as a nonflavivirus control. Viral preparations used for specificity testing contained at least  $10^5$  plaque forming units/ml.

# Preparation of RNA

Viral RNA was extracted with a mixture of guanidine isothiocyanate-phenol-chloroform by modified methods mescribed previously [2]. 100 ml of each virus suspension was mixed with solution D (4 M guanidine isothiocyanate, 25 mM sodium citrate pH 7.0,  $0.5^{\circ}$ , sarcosyl, and 0.1 M 2-mercaptoethanol). Sodium acetate, pH 4.0, was added to yield a final concentration of 0.2 M, and the viral RNA was extracted with an equal volume of water saturated phenol and one fifth volume of chloroform:isoamyl alcohol (49:1). The sample was then mixed vigorously for 10 sec and cooled on ice for 15 min and centrifuged at 10 000 rpm in a sorvall 33-34 rotor (Dupont, Wilmington, DE) for 20 min at 4°C. The top aqueous layer containing viral RNA was precipitated with an equal volume of ice cold isopropyl alcohol for one h at  $-20^{\circ}$ C. The precipitated RNA was then centrifuged and the pellet was washed with 70% ethanol. After centrifugation, the pellet was dried using a Savant (Farmingdale, NY) Speed Vac concentrator.

#### Synthetic DNA oligometic probes and primers

Sense and antisense primers were designed with the use of a computer-assisted analysis of the genomic RNA of several different flaviviruses which have been fully sequenced. The primer sequences chosen were from conserved regions of the envelope protein except for a few internal mismatches. Specific probes were selected for each virus from unique base sequences within the PCR amplified regions. Reagent grade synthetic DNA oligomeric primers and probes (Table 1) were produced by Synthecell (Rockville). Table 2 shows the comparison of viral sequences with the flaviviral primers, and the length of PCR products amplified by the primers for each virus. For internal mismatches, we inserted the neutral nucleoside inosine at two places.

## Detection of flaviviruses by PCR

Oligomer <sup>a</sup>	Number <sup>b</sup>	Sequence
Primers		
Flavi 1 ( – ) Flavi 2 ( + )		CCTCCAAIGGAICCAAAATCCCA GGATGGGGIAATGGITGTGG
Probes		
DEN-2 WN SLE KUN	1419 1399 1395 1378	AGTCAAGATAACACCACAGAGC GGCCCGACGACCGTTGAATCTC GGTTCAACGGACTCTACGTCAC GGACCAACTACCGTGGAATCGC

Table 1.	Sequences	of oligomer	DNA	primers	and	probes	for	PCR	amplifica	tion
of viral RNA										

\* Oligomers were either of genomic (+) or antigenomic (-) sense

<sup>b</sup> Number corresponds to nucleotide base sequence. DEN-2 specific (7). WN specific (1), SLE specific (23), and KUN specific (3)

<sup>c</sup> Sequences are presented in the 5' to 3' direction

....

Table 2. Comparison of viral sequences with flaviviral primers

Virus strain	Viral sequences (5'-3')	Number <sup> j</sup>	Predicted size of PCR product (bp)
DEN 1ª	1. CCTCCTATAGAACCGAAGTCCCA	2165	
	2. GGCTGGGGGCAATGGTTGTGG	1205	983
DEN 2 <sup>b</sup>	1. CCTCCCAGAGATCCAAAATCCCA	2194	
	2. GGATGGGGAAATGGATGTGG	1234	986
DEN3 <sup>c</sup>	1. CCACCCACTGATCCAAAGTCCCA	2194	
	2. GGCTGGGGGAAACGGTTGTGG	1234	986
DEN 4 <sup>d</sup>	1. CCACCAACGGAACCAAAATCCCA	2194	
	2. GGGTGGGGGCAATGGCTGTGG	1234	986
WN۴	1. CCTCCAACTGATCCAAAATCCCA	2230	
	2. GGATGGGGAAATGGCTGCGG	1264	986
SLE'	1. CCTCCAATAGATCCAAAGTCCCA	2238	
	2. GGATGGGGTAACGGATGTGG	1260	1001
KUN <sup>s</sup>	1. CCTCCAACCGATCCAAAGTCCCA	2221	
	2. GGTTGGGGGCAATGGGTGCGG	1243	1001
JEV <sup>b</sup>	1. CCTCCAATAGAGCCAAAGTCCCA	1939	
	2. GGGTGGGGGCAACGGATGTGG	964	998
11 <sup>1</sup>	1. CCTCCAGCGGAGCTGAAATCCCA	2225	
	2. GGCTGGGGGCAATGGCTGTGG	1271	976

Mismatches in viral sequences from Flavi 1 (+) and Flavi 2 (+) primers are in italics <sup>a</sup> Mason et al. [17]; <sup>b</sup> Hahn et al. [7]; <sup>c</sup> Osatomi et al. [22]; <sup>d</sup> Mackow et al. [15]; <sup>e</sup> Castle et al. [1]; <sup>f</sup> Trent et al. [23]; <sup>s</sup> Coia et al. [3]; <sup>b</sup> McAda et al. [19]; <sup>i</sup> Rice et al. [21]. <sup>i</sup> Number indicates the map site at which 5' end of Flavi primess hybridize on each viral strain genome

## Reverse transcriptase-polymerase chain reaction assay (RT-PCR)

Virus specific cDNA was amplified by RT-PCR using the flaviviral primers. The dry RNA pellets were resupended in 10µl of sterile distilled water, and 2µl of primer 1 (11.8 pmoles) was added. The RNA suspension was heated at 68 °C for 3 min, cooled on ice and added to 18 µl of reaction mixture containing 50 mM Tris pH 8.8, 200 mM ammonium sulphate. 25 mM MgCl<sub>2</sub> 10 mM dithiothreitol, 0.1% triton X-100, 100 mg/ml BSA, 275 mM deoxynucleotide triphosphate, 25 units RNAsin (human placental ribonuclease inhibitor; Promega, Madison, WI) and 10 units of reverse transcriptase in the total volume 30 µl. The mixture was incubated at 42 °C for 40 min and cooled on ice. Polymerase chain reaction amplification of cDNA was performed by adjusting the mixture to 50 mM Tris pH 8.8, 200 mM ammonium sulphate, 25 mM MgCl<sub>2</sub> 200 mM deoxynucleotide triphosphate, 0.3 mM primer 1 and 0.3 mM primer 2 and 0.025 units/ml of Amplitaq DNA polymerase (Perkin-Elmer Cetus Corporation) in a total volume of 100 µl. To deduce the optimal reaction conditions, two magnesium concentrations (1.5 mM and 2.5 mM) and three different numbers of total cycles (25, 30 and 35) were investigated. Following PCR the samples "the cooled to 4  $^{\circ}$ C. A 10  $\mu$ l aliquot of each sample was electrophoresed on a 4-20% NOVEX TBE polyacrylamide gradient gel (Encinitas) and stained with ethidium bromide using standard method [16]. Stained gels were photographed on a light box using Polaroid type 667 film. Slot blot hybridization of the PCR samples was done on Hybond-N membrane.

#### Preparation of labelled oligomeric probes

ţ

Oligomeric DNA probes specific for each virus were 5'-end labeled with <sup>32</sup>P using T-4 DNA Kinase (Boehringer Mannheim, Indianapolis, IN) and partially purified using Sephadex G-25 column chromatography according to standard method [16]. Radiolabeled synthetic probes were diluted to 10<sup>6</sup> cpm/ml in hybridization buffer before use.

#### Nucleic acid hybridization

A 10 µl aliquot of each amplified DNA sample was treated with 1µl of 3 M sodium hydroxide and incubated for 30 min at 70 °C. Samples were neutralized with two volumes of 2 M ammonium acetate, vortexed and cooled on ice. An aliquot of each sample was slotted onto Hybond N-nylon membrane using a Stratalinker UV box (Stratagene) according to the manufactures instructions. Membranes were treated with an excess volume of prehybridization buffer (6  $\times$  SSC [1  $\times$  SSC = 0.15 M sodium chloride, 0.015 M sodium citrate], 5  $\times$ Denhardt's solution  $[1 \times Denhardt's = 0.02\% polyvinylpyrolidoen, 0.02\% Ficoll, 0.02\%$ bovine serum albumin], 0.5% sodium dedecyl sulfate, 0.05% sodium pyrophosphate and 0.1 mg/ml sheared salmon sperm DNA) for 2 h at 37  $^{\circ}$ C in a heat sealed bag. The membranes were then hybridized with <sup>32</sup>p labelled oligomeric probes overnight at 37 °C in hybridization buffer (6  $\times$  SSC, 1  $\times$  Denhardt's solution, 0.5% sheared salmon sperm DNA, 0.15% sodium pyrophosphate). Membranes were washed twice with an excess of  $2 \times SSC$ , 1% sodium dodecyl sulfate for 15 min at ambient temperature, twice with  $0.2 \times SSC$  and 0.1% sodium dodecyl sulfate for 15 min at 37 °C, and twice with  $0.2 \times SSC$  and 0.1% sodium dodecyl sulfate for 15 min at 42 °C. Washed membranes hybridized with <sup>32</sup>P labelled probe were air dried and exposed to Kodak X-OMAT XAR-5 film (Eastman Kodak) and Cronex lightening plus intensifying screen (Dupont).

#### Clinical specimens

Human serum samples were obtained from patients with clinically characterized dengue-2 infection were tested by the RT-PCR assay. These samples had previously been shown

to contain DEN-2 viruses by cell culture isolation and identification of virus serotype by indirect immunofluorescence assay (IFA) with dengue virus type-specific monoclonal antibodies.

# Results

The specificity of the flaviviral primers was evaluated by RT-PCR employing flaviviral, nonflaviviral infected and uninfected negative control cell culture supernatants. The combination of 35 cycles at 1.5 mM MgCl<sub>2</sub> and 42 °C annealing provided the highest level of sensitivity and specificity. The RT-PCR amplified the RNA of DEN-2, WN, SLE, and KUN viruses, but failed to amplify JE, YF, DEN-1, 3, and 4. The size of the amplified DNA was consistent with the predicted for the target region in the viral genomes (between 986-1001 bp) (Table 2). No PCR product was obtained with flaviviral primers used for rhinovirus and uninfected cell culture supernatant. The PCR products demonstrated by ethidium bromide straining are shown in Fig. 1.

The flaviviruses were identified by nucleic acid hybridization of specific oligomeric DNA probes with amplified cDNA. Slot blot hybridization was chosen as a method of evaluation because it allowed for simultaneous identifi-



Fig. 1. Analysis of polymerase chain reaction amplification products separated by electrophoresis on a 20% polyacrylamide gradient gel and stained with ethidium bromide. M 1 Kb; DNA ladder standard. 1 DEN-2; 2 WN; 3 SLE; 4 KUN; 5 Rhinovirus; 6 Uninfected cell culture supernatant



Fig. 2. Slot blot hybridization of the PCR products resulting from the enzymatic amplification of RNA extracted from uninfected, DEN-2, WN, SLE, and KUN infected cell cultures. 1 DEN-2; 2 WN; 3 SLE, and 4 KUN specific probes



Fig. 3. Sensitivity of the reverse transcriptase-polymerase chain reaction assay to detect the viruses. PCR products from different amount of RNA from uninfected, DEN-2, WN, SLE, and KUN infected cell cultures were slot blotted and hybridized with radiolabeled probes. 1 DEN-2; 2 WN; 3 SLE; and 4 KUN

cation using different synthetic probes. Amplified cDNA form uninfected, DEN-2, WN, SLE and KUN were each hybridized against specific oligomeric DNA probes (Table 1). Each oligomeric probe reacted only with the homologous virus (Fig. 2).

In order to determine the sensitivity of the flaviviral primers, titration experiments were done with DEN-2, WN, SLE and KUN viruses. RNA was extracted from DEN-2, WN, SLE, and KUN infected cell culture supernatants and quantitated by spectrophotometry. Three 10 fold dilutions of each RNA sample was made in distilled water. Ten  $\mu$ l of each dilution (1 pg, 0.1 pg, and 0.01 pg RNA) was used for RT-PCR amplification. Following amplification, 1 pg of RNA from DEN-2 and WN and 0.1 pg of RNA from SLE and KUN was detected directly by ethidium bromide staining. The amplified product from

34

#### Detection of flaviviruses by PCR

Table 3.	Comparison of RT-PCR/slot	blot hybridization and virus isolation
	for the identification of DEN-	-2 viruses from human serum

Method	No. of serum samples of DEN-2 virus type				
Virus isolation	13				
RT-PCR and slot blot hybridization	12				

each virus only reacted with the homologous oligomeric probe by slot blot hybridization. Faint bands were detected with the amplified products from 0.1 pg RNA of all four viruses by nucleic acid hybridization (Fig. 3).

Sera from thirteen human viremic patients and three virus negative control sera were tested by RT-PCR assay. Amplified DNA was first characterized by gel electrophoresis and staining by ethidium bromide, followed by slot blot nucleic acid hybridization. Table 3 summarizes the results comparing identification by the RT-PCR assay with identification by virus isolation in cell culture and subsequent typing by the IFA with type-specific monoclonal antibodies. In all but one instance, DEN-2 viruses were correctly detected and typed by the RT-PCR assay, compared with virus isolation. Negative samples were negative, and one sample containing DEN-2 virus was not found positive by the RT-PCR method.

## Discussion

All known flaviviruses share short conserved sequences. The gene which codes for the envelope protein exhibits sequences with minimal variations among the several different flaviviruses. This conservation allowed the selection of a pair of flaviviral primers which could be used for amplification of the envelope gene from several different flaviviruses even though they are not perfectly complementary within the short 20–23 nucleotides length of the primers.

Previous investigators have described the PCR assay for St. Louis encephalitis (SLE), Japanese encephalitis (JE), yellow fever (YF), dengue 2 (DEN-2) and dengue-4 using different sets of primers for each virus [5]. Here, we evaluated RT/PCT amplification of RNA from four different viruses within the flavivirus group using a single set of flaviviral primers followed by nucleic acid hybridization with radiolabeled synthetic oligomeric probes. Twenty-three base antisense and twenty base sense primers (Table 2) amplified the predicted size of fragments from DEN-2, WN, SLE, and KUN. An internal 22 base oligonucleotide from each member served as a probe. Using these primers, a protocol was developed that detected as little as 1.0-0.1 pg of RNA from DEN-2, WN, SLE and KUN after ethidium bromide straining. The more occurrence of mismatches and or mismatches closer to 3' prime binding site may explain the lesser efficiency of amplification with YF, JE, DEN-1, 3, and 4 viruses. Important considerations

35

in developing a PCR protocol are optimizing the number of cycles, annealing temperature and magnesium concentration. At an annealing temperature greater than 42 °C there was no amplification, and at lower temperatures, there were additional nonspecific bands.

Since a single set of flaviviral primers was designed to amplify different viruses it was necessary to identify each virus type after amplification. The specificity of the amplified fragment was confirmed by an internal sequence specific oligonucleotide probe. The use of radiolabeled oligonucleotide probe allowed for an additional level of specificity  $(96-100^{\circ})$  for detection of PCR products.

Because of the high degree of sensitivity and specificity, the PCR method described here has a potential application for the routine diagnosis of flaviviral infections. The diagnostic usefulness of our assay is demonstrated by the analysis of human serum samples containing dengue virus. Another decided advantage of PCR is speed; the entire procedure can be completed in 8 h and multiple samples can be tested simultaneously with minimal technical effort. However, the current PCR assay is limited in its usefulness because in only amplified 4 of the 9 flavivirus recognized. This limitation may be overcome by using primer pairs with greater homology to the other flaviviruses not amplified by Flavi-1 and Flavi-2 or by constructing degenerate primers.

## Acknowledgements

This research was supported by Naval Medical Research and Development Command work units 3M263002D807-AH-1279 and 3M162787A870-AQ-1299. We thank Dr. R. Putnak for helpful discussions and the critical review of this manuscript.

## References

- Castle E, Nowak T, Leidner U, Wengler G, Wengler G (1985) Sequence analysis of the viral core protein and the membrane associated protein V1 and NV2 of the Flavivirus West Nile virus and of the genome for these proteins. Virology 145: 227-236
- 2. Chomozynski P, Sacchi N (1987) Single step method of RNA isolation by acid guanidine thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
- 3. Coia G, Parker MD, Speight G, Byrne ME, Westaway EG (1988) Nucleotide and complete amino acid sequences of kunjin virus. J Gen Virol 69: 1-21
- Deubel V, Laille M, Hugnot JP, Chungue E, Guesdon JL, Drouet MT, Bassot S. Chevrier N (1990) Identification of dengue sequences by genomic amplification: rapid diagnosis of dengue virus serotypes in peripheral blood. J Virol Methods 30: 41-54
- Eldadah ZA, Asher DM, Godec MS, Pomeroy L, Goldfarb LG, Feinstone SM, Levitan H, Gibbs CJ Jr, Gajdusek CD (1991) Detection of flavivirus by reverse transcriptase polymerase chain reaction. J Med Virol 33: 260-267
- Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trute A, Parker D, Barbara JAJ, Contreras M, Aloysius S (1990) Detection of hepatitis C viral sequences in blood donations by nested polymerase chain reaction and prediction of infectivity. Lancet i: 1419-1422
- 7. Hahn YS, Galler R, Hunkapillar T, Dalrymple JM, Straus EG (1988) Nucleotide sequence of dengue-2 RNA and comparison of the encoded proteins with those of other flaviviruses. Virology: 167-180

36

Detection of flaviviruses by PCR

- 8. Halstead SB (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239: 476-481
- Henchal EA, Gentry MK, McCown JM, Brandt WE (1982) Dengue virus specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31: 830-836
- Henchal EA, McCown JM, Seguin MC, Gentry MK, Brandt WE (1983) Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay. Am J Trop Med Hyg 32: 164-169
- Henchal EA, Polo SL, Vorndam V, Yaemsiri C, Innis BL, Hoke CH (1990) Sensitivity and specificity of a universal primer set for the rapid diagnosis of dengue virus infection by polymerase chain reaction and nucleic acid hybridization. Am J Trop Med Hyg 45: 418-428
- 12. Ho-Terry L, Terry GM, Londesborough P (1990) Diagnosis of foetal rubella virus infection by polymerase chain reaction. J Gen Virol 71: 1607-1611
- 13. Kuberski TT, Rosen L (1977) A simple technique for the detection of dengue antigen in mosquitoes by immunofluorescence. Am J Trop Med Hyg 26: 533-537
- Lifson AR, Stanley M, Pane J, O'Mally PM, Wilber JC, Stanley A, Jeffery B. Rutherford GW, Sohmer PR (1990) Detection of human immunodeficiency virus DNA using the polymerase chain reaction in a well characterized group of homosexual and bisexual men. J Infect Dis 161: 436-439
- Mackow C, Makino Y, Zhao B. Zhang YM, Markoff L, Buckler-White A, Guoler M, Chanock R, Lai CJ (1987) The nucleotide sequence of dengue type 4 virus: Analysis of genes coding for nonstructural proteins. Virology 159: 217-228
- 16. Maniatis T, Fritsch EF, Sambrook J (1982) Molecular cloning: a laboratory manual. Cold Spring Harboi Press. Cold Spring Harbor
- 17. Mason PW, McAda PC, Mason TL, Fournier MJ (1987) Sequence of the Dengue 1 virus genome in the region encoding the three structural proteins and the major nonstructural protein NS1. Virology 161: 262-267
- 18. Matthews REF (1979) Classification and nomenclature of viruses. Third report of the International Committee on Taxonomy of Viruses. Intervirology 12: 129-296
- McAda PC, Mason PW, Schmaljohn CS, Dalrymple JM, Mason TL, Fournier MJ (1987) Japanese encephalitis virus capsid protein (3' end), membrane protein, envelope protein, nonstructural proteins NS1 and NS2, complete cds and nonstructural protein NS3 (3' end) mRNA. Virology 158: 448-460
- 20. Monath T (1990) Flaviviridae. In: Mandell GL, Douglas RG, Bennett JE (eds) Principles and practice of infectious diseases. Churchill Livingston, New York, pp 1248-1251
- 21. Rice M, Lenches EM, Eddy R, Shin SEJ, Sheets RL, Strauss JH (1985) Nucleotide sequences of Yellow fever virus: implications for flavivirus gene expression and evolution. Science 229: 726-733
- 22. Osatomi KFI, Tsuru D, Shiba T, Sakari Y, Sumiyoshi H (1988) Nucleotide sequences of Dengue Type 3 virus genomic RNA encoding viral structural proteins. Virus Genes 2: 99-108
- 23. Trent DW, Kinney RM, Johnson BJB, Vorndam AV, Grant JA, Deubel V, Rice CM, Hahn C (1987) Partial nucleotide sequences of St. Louis encephalitis virus RNA: structural proteins, NS1, ns2a and ns2b. Virology 156: 293-304

Authors' address: Dr. B. Puri, IDTA, NMRI, 17B, Mail Stop 7, 8901 Wisconsin Avenue. Bethesda, MD 20889-5055, U.S.A.

Received February 17, 1993